Episode
Michael Langer: Biotech Investing in the Data Age
- Podcast
- Behind the Breakthroughs
- Published
- Oct 29, 2025
- Duration seconds
- 2941
- Processing state
not_requested- Canonical source
- https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/michael-langer-biotech-investing-in-the-data-age
Actions
POST https://stenobird.com/v1/public/podcasts/behind-the-breakthroughs-7055075/episodes/michael-langer-biotech-investing-in-the-data-age/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/behind-the-breakthroughs-7055075/michael-langer-biotech-investing-in-the-data-age.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
If you work in biotech, the name Langer likely rings a bell. Robert Langer—the MIT legend behind Moderna and dozens of biotech startups—has become synonymous with innovation. Now, a new Langer is stepping forward. Michael Langer, Robert’s son, represents a new generation of investors rethinking biotech in the age of AI and data. Rather than chasing hype, he’s applying lessons from a lifetime around scientists to build a more disciplined, informed investment philosophy. As co-founder of T.Rx Capital, he’s helping shape the next phase of tech-enabled biotech—and exploring what truly drives success in precision medicine. Produced and hosted by Jonathan D. Grinstein, PhD Audio mixed and mastered by David Mosely Brought to you by Inside Precision Medicine (SAGE Publishing) Hosted on Acast. See acast.com/privacy for more information.